Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634620 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL21581529 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL21580890 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL21580891 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL10552459 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL23700733 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL24815077 | 0.81 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL26027991 | 0.81 | HTR2A (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL554117 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL554167 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116600806-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2023-08-15 | — | — | CN | claimed |
| EP-3241856-B1 | POLYURETHANE CATALYST AND APPLICATION THEREOF | JIANGSU OSIC PERFORMANCE MAT CO LTD (CN) | 2021-08-18 | — | — | EP | claimed |
| US-10889681-B2 | Polyurethane catalyst and application thereof | JIANGSU OSIC PERFORMANCE MATERIALS CO. LTD. (CN) | 2021-01-12 | — | — | US | claimed |
| US-20180273671-A1 | POLYURETHANE CATALYST AND APPLICATION THEREOF | JIANGSU OSIC PERFORMANCE MATERIALS CO. LTD. (CN) | 2018-09-27 | — | — | US | claimed |
| EP-3241856-A1 | POLYURETHANE CATALYST AND APPLICATION THEREOF | Jiangsu Osic Performance Materials Co. Ltd. (CN) | 2017-11-08 | — | — | EP | claimed |
| CN-106892907-A | Quinazoline compounds and its application containing acylhydrazone structure | 江西科技师范大学 | 2017-06-27 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | THE PENN STATE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-1111629-A | 5-vinyl-, 5-ethynylquinolone-and 5-vinyl-, 5-ethynylnaphthyridonecarboxylic acids | BAYER AG (DE) | 1995-11-15 | — | — | CN | disclosed |
| EP-0671391-A1 | 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids | BAYER AG (DE) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0523512-A1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1993-01-20 | — | — | EP | disclosed |
| EP-0373531-A1 | Novel pyridobenzoxazine derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-06-20 | — | — | EP | disclosed |
| US-4889857-A | BACTERICIDES; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0311948-A2 | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | SLC6A2 4281/4885SLC6A4 4444/4885SLC6A3 4382/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SLC6A2 4876/4885SLC6A4 4860/4885SLC6A3 4850/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SLC6A2 4876/4885SLC6A4 4860/4885SLC6A3 4850/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | SLC6A2 4280/4885SLC6A4 3414/4885SLC6A3 2929/4885 |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | CYP3A4, CYP4B1, CYP2C9 | SLC6A2 3690/4885SLC6A4 1853/4885SLC6A3 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.